Skip to main content
SpringerLink
Log in

Pretomanid in drug-resistant tuberculosis: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Pretomanid, a nitroimidazoxazine antimycobacterial agent, presents a valuable option for the treatment of adults with pulmonary extensively drug-resistant (XDR) tuberculosis (TB) or treatment-intolerant or nonresponsive multidrug-resistant (MDR)-TB when used as part of an all-oral combination regimen with bedaquiline and linezolid. In the pivotal phase III Nix-TB trial, a combination regimen of pretomanid, bedaquiline, and linezolid for 6 months had a high treatment success rate. Besides the demonstrated effectiveness, the pretomanid, bedaquiline, and linezolid combination has other benefits, including the convenience of oral administration, a relatively short treatment duration, and a relatively low potential for drug-drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. Global tuberculosis report. 2019. https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1. Accessed 23 Apr 2020.

  2. World Health Organization. Global tuberculosis report 2019—fact sheet. 2019. https://www.who.int/tb/publications/factsheet_global.pdf?ua=1. Accessed 23 Apr 2020.

  3. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195195.

    Article  Google Scholar 

  4. Dheda K, Gumbo T, Maartens G, et al. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9):820–6.

    Article  CAS  Google Scholar 

  5. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1. Accessed 23 Apr 2020.

  6. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis – an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93–e142.

    Article  Google Scholar 

  7. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962–6.

    Article  CAS  Google Scholar 

  8. Manjunatha U, Boshoff HIM, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol. 2009;2(3):215–8.

    Article  CAS  Google Scholar 

  9. Singh R, Manjunatha U, Boshoff HIM, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322(5906):1392–5.

    Article  CAS  Google Scholar 

  10. Li S-Y, Tasneen R, Tyagi S, et al. Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2017;61:9.

    Google Scholar 

  11. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52(4):1522–4.

    Article  CAS  Google Scholar 

  12. Tasneen R, Betoudji F, Tyagi S, et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2016;60(1):270–7.

    Article  CAS  Google Scholar 

  13. Tasneen R, Tyagi S, Williams K, et al. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52(10):3664–8.

    Article  CAS  Google Scholar 

  14. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2005;49(6):2289–93.

    Article  CAS  Google Scholar 

  15. Xu J, Li S-Y, Almeida DV, et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob Agents Chemother. 2019;63:5.

    Google Scholar 

  16. Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738–47.

    Article  CAS  Google Scholar 

  17. Diacon AH, Dawson R, du Bois J, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012;56(6):3027–31.

    Article  CAS  Google Scholar 

  18. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015;191(8):943–53.

    Article  CAS  Google Scholar 

  19. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012;380(9846):986–93.

    Article  CAS  Google Scholar 

  20. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902.

    Article  CAS  Google Scholar 

  21. Pretomanid tablets: US prescribing information. New York (NY): TB Alliance; 2019.

  22. European Medicines Agency. CHMP summary of positive opinion for pretomanid FGK. 2020. https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-pretomanid-fgk_en.pdf. Accessed 23 Apr 2020.

  23. Dogra M, Palmer BD, Bashiri G, et al. Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver. Br J Pharmacol. 2011;162(1):226–36.

    Article  CAS  Google Scholar 

  24. Baptista R, Fazakerley DM, Beckmann M, et al. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Sci Rep. 2018;8(1):5084.

    Article  Google Scholar 

  25. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005;49(6):2294–301.

    Article  CAS  Google Scholar 

  26. Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2019;38(7):1293–6.

    Article  CAS  Google Scholar 

  27. Somasundaram S, Anand RS, Venkatesan P, et al. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor. BMC Microbiol. 2013;13:218.

    Article  Google Scholar 

  28. Tasneen R, Li S-Y, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011;55(12):5485–92.

    Article  CAS  Google Scholar 

  29. Tasneen R, Williams K, Amoabeng O, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 2015;59(1):129–35.

    Article  Google Scholar 

  30. Haver HL, Chua A, Ghode P, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(9):5316–23.

    Article  CAS  Google Scholar 

  31. Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother. 2009;53(9):3720–5.

    Article  CAS  Google Scholar 

  32. Winter H, Ginsberg A, Egizi E, et al. Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. Antimicrob Agents Chemother. 2013;57(11):5516–20.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: A. D. Baughn, Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA; C. L. Daley, Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, CO, USA. During the peer review process, TB Alliance, the marketing-authorization holder of pretomanid, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Matt Shirley

Authors
  1. Matt Shirley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matt Shirley.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

M. Shirley is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.

Additional information

Enhanced material for this Adis Drug Q&A can be found at https://doi.org/10.6084/m9.figshare.12278645.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shirley, M. Pretomanid in drug-resistant tuberculosis: a profile of its use. Drugs Ther Perspect 36, 273–279 (2020). https://doi.org/10.1007/s40267-020-00743-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-020-00743-9

Search

Navigation